Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. director Roy D. Baynes carried out an exercise-and-sell transaction involving company stock. On May 1, 2026, he exercised stock options to acquire 9,750 shares of common stock at $6.82 per share, then sold 9,750 shares in an open-market transaction at $44.22 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025, indicating it was scheduled in advance. Following these transactions, Baynes directly holds 37,500 shares of Travere common stock, and the exercised option is now fully vested and exercisable with no remaining derivative position from that specific grant.
Travere Therapeutics reported strong first quarter 2026 growth driven by FILSPARI. Total revenue was $127.2 million, up from $81.7 million a year earlier, as U.S. net product sales rose to $124.5 million, largely from FILSPARI. GAAP net loss narrowed to $37.1 million, or $0.40 per share, while non-GAAP results improved to net income of $4.1 million, or $0.05 per share. FILSPARI U.S. net product sales reached $105.2 million, an 88% year-over-year increase, supported by 993 new patient start forms for IgA nephropathy. The FDA also approved FILSPARI for focal segmental glomerulosclerosis, expanding the U.S. addressable population for FILSPARI to more than 100,000 patients. Travere restarted enrollment in its Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria and ended the quarter with $264.7 million in cash, cash equivalents and marketable securities.
Morgan Stanley Smith Barney LLC filed a Form 144 notice for the proposed sale of 20,000 shares of Common Stock related to a stock option exercise to occur on 05/04/2026 with cash proceeds. The filing lists multiple sales by Elizabeth Reed during the prior three months, including 37,500 and other dispositions with aggregate proceeds shown per line items.
TVTX filing a Rule 144 notice reporting a stock option exercise and planned sale of 20,000 shares on 05/04/2026. The form lists cash settlement for the exercise. The filing also discloses prior sales in the last three months: 1,018 shares on 04/15/2026 and 7,215 shares on 04/14/2026, with dollar amounts shown for each transaction.
Roy Baynes filed a Form 144 proposing to sell 9,750 shares of Common Stock via a stock option exercise on 05/01/2026 for cash, through Morgan Stanley Smith Barney LLC. The form also discloses two prior sales in the past three months: 32,750 shares on 04/14/2026 for $1,352,130 and 10,000 shares on 04/06/2026 for $330,000.
Travere Therapeutics ownership disclosure: Vanguard Capital Management reports beneficial ownership of 4,699,424 shares of Common Stock, representing 5.09% of the class as reported for the period ending 03/31/2026. The filing shows sole voting power over 653,612 shares and sole dispositive power over 4,699,424 shares. The disclosure states these holdings are exercised across Vanguard affiliates and include securities held for client accounts and Vanguard funds.
Travere Therapeutics, Inc. Chief Research Officer William E. Rote reported an open-market sale of 9,100 shares of common stock at $39.09 per share. After this transaction, he directly holds 113,987 shares. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan and includes shares sold to cover tax obligations from vesting performance restricted stock units.
Travere Therapeutics, Inc. (TVTX) reports that its officer, William E. Rote, intends to sell 9,100 common shares on approximately April 22, 2026, with an aggregate market value of $355,719.00. The notice lists a Rule 10b5-1 plan adoption date of May 29, 2025. Rote also reported selling 12,446 common shares on February 3, 2026, for gross proceeds of $409,100.02.
Travere Therapeutics director Gary A. Lyons exercised stock options and sold shares on the same day. He exercised options for 8,000 shares of Common Stock at an exercise price of $16.3300 per share, then sold 8,000 shares at $41.0700 per share.
The sale was carried out under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 11, 2025, and involved shares underlying options expiring on May 18, 2026. Following these transactions, he directly holds 57,500 shares of Travere Therapeutics Common Stock.